Role of the cross-talk between estrogen receptors and peroxisome proliferator-activated receptor gamma in daidzein's prevention and treatment of osteoporosis in ovariectomized rats

National Medical Journal of China

Volumn 89, Issue 42, 2009, Pages 2972-2975

  Zou, Shi En ^a   Zhang, Shao Fen ^a   Zhang, Rui ^a   Zhang, Jing ^a  

^a OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Daidzein; Osteoporosis; Peroxisome proliferator activated receptor ; Receptors, estrogen

Indexed keywords

DAIDZEIN; ESTROGEN RECEPTOR; ISOFLAVONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; ARTICLE; FEMALE; METABOLISM; OSTEOPOROSIS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; FEMALE; ISOFLAVONES; OSTEOPOROSIS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN;

EID: 84871456710     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.42.007     Document Type: Article

References (16)

1. O'Connell D, Robertson J, Henry D, et al. A systemic review of the sekeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. Climacteric, 1998, 1: 112-123.
2. Writing Group for the Women's Health Initiative Investigations. Risks and Benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative controlled trial. JAMA, 2002, 288; 321-333.
3. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and the risk of ovarian cancer. JAMA, 2002, 288: 334-341.
4. Reinwald S, Weaver CM. Soy Isoflavones and bone health; a double-edged sword? J Nat Prod, 2006, 69: 450-459.
5. Bitto A, Burnett BP, Polito F, et al. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol, 2008, 155: 896-905.
6. Sharan K, Siddiqui JA, Swarnkar G, et al. Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies. Curr Med Chem, 2009, 16: 1138-1157.
7. Zou SE, Zhang SF, Jiang L, et al. The dose-dependent effect of dadzein on osteoporosis in the ovariectomized rats. Chin J Osteopor, 2008, 14: 177-182.
8. Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol, 2004, 4: 290-294.
9. Tang D, Jin BQ, Lv L, et al. Effect of daidzein and puerarin on biochemical markers of bone metabolism in the ovariectomized rats. Chin J Clini Rehab, 2006, 10: 40-42.
10. Rickettsa ML, Moorea DD, Banzb WJ, et al. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem, 2005, 16: 321-330.
11. Onoe Y, Miyaura C, Ohta H, et al. Expression of estrogen receptor beta in rat bone. Endocrinology, 1997, 138: 4509-4512.
12. Arts J, Kuiper GG, Janssen JM, et al. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology, 1997, 138: 5067-5070.
13. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor alpha and estrogen receptor beta in the presence of a partial estrogen agonist/antagonist. Mol Pharmacol, 1998, 54: 105-102.
14. Dang ZC, Lowik CW. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res, 2004, 19: 853-861.
15. Dang ZC, Audinot V, Papapoulos SE, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem, 2003, 278: 962-967.
16. Dang ZC, Clemens L. Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol Metab, 2005, 16: 207-213.